This was the stock's fourth consecutive day of gains.
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report), with a ...
As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value ...
Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...
Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback